Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 9:03 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 439 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: Eisai Inc. Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Single Dose Study to Determine the Safety, Tolerability, and Pharmacokinetic Properties of Lorcaserin Hydrochloride (BELVIQ) in Obese Adolescents From 12 to 17 Years of Age

NCT02022956
View directory record Official record
Conditions
Pharmacokinetics in Obese Adolescents
Interventions
Lorcaserin
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
12 Years to 17 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2013
U.S. locations
2
States / cities
Philadelphia, Pennsylvania • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 17, 2019 · Synced Oct 14, 2026, 9:03 AM EDT
Completed Phase 2 Interventional

Safety and Tolerability of E5555 and Its Effects on Markers of Intravascular Inflammation in Subjects With Coronary Artery Disease

NCT00312052
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
E5555, Placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
45 Years to 80 Years
Enrollment
720 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
2
States / cities
Gainesville, Florida • Alpena, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 5, 2016 · Synced Oct 14, 2026, 9:03 AM EDT
Approved For Marketing No phase listed Expanded access

An Expanded Access Program With Lenvatinib for the Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer

NCT02211222
View directory record Official record
Conditions
Differentiated Thyroid Cancer
Interventions
Lenvatinib
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Timeline
Ends 2015
U.S. locations
13
States / cities
La Jolla, California • Stanford, California • Torrance, California + 10 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2016 · Synced Oct 14, 2026, 9:03 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study To Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2086 in Healthy Adult and Elderly Participants

NCT05745207
View directory record Official record
Conditions
Healthy Volunteers
Interventions
E2086, Placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 2, 2024 · Synced Oct 14, 2026, 9:03 AM EDT
Terminated Phase 2 Interventional Results available

A Study of Gliadel Followed by Avastin + Irinotecan for Glioblastoma Multiforme (GBM)

NCT00735436
View directory record Official record
Conditions
Malignant Glioma, Glioblastoma Multiforme, Gliosarcoma
Interventions
Gliadel/Avastin/CPT-11
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 11, 2013 · Synced Oct 14, 2026, 9:03 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Effect of Diltiazem Extended Release on the Pharmacokinetics of E2027 in Healthy Subjects

NCT02947711
View directory record Official record
Conditions
Healthy Subjects
Interventions
E2027, Diltiazem ER
Drug
Lead sponsor
Eisai Co., Ltd.
Industry
Eligibility
18 Years to 50 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Mar 7, 2017 · Synced Oct 14, 2026, 9:03 AM EDT
Completed Phase 2 Interventional Results available

Palonosetron Versus Ondansetron for the Prevention of Nausea and Vomiting

NCT01031498
View directory record Official record
Conditions
Acute Myelogenous Leukemia, Chemotherapy-induced Nausea and Vomiting
Interventions
Ondansetron, Palonosetron
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 7, 2012 · Synced Oct 14, 2026, 9:03 AM EDT
Withdrawn Phase 1 Interventional

A Study of Stimulator of Interferon Genes (STING) Agonist E7766 in Non-muscle Invasive Bladder Cancer (NMIBC) Including Participants Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy, INPUT-102

NCT04109092
View directory record Official record
Conditions
Urinary Bladder Neoplasms
Interventions
E7766
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
9
States / cities
Gilbert, Arizona • Los Angeles, California • Santa Monica, California + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 14, 2020 · Synced Oct 14, 2026, 9:03 AM EDT
Completed Phase 2 Interventional

Study to Evaluate the Efficacy, Safety, and Tolerability of E7070 in Metastatic Breast Cancer Patients

NCT00080197
View directory record Official record
Conditions
Breast Neoplasms, Metastases
Interventions
E7070
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
34
States / cities
Birmingham, Alabama • Hoover, Alabama • Sedona, Arizona + 31 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2006 · Synced Oct 14, 2026, 9:03 AM EDT
Completed Phase 2 Interventional Results available

Phase 2, Parallel Group, Rollover Study of AKR-501 in Patients With ChronicITP Who Completed 28 Days of Study Treatment in Protocol 501-CL-003

NCT00625443
View directory record Official record
Conditions
Idiopathic Thrombocytopenic Purpura
Interventions
Blinded (placebo), Open Label (Avatrombopag tablets), Blinded (Avatrombopoag tablets)
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
12
States / cities
Anaheim, California • Bakersfield, California • Manchester, Connecticut + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2018 · Synced Oct 14, 2026, 9:03 AM EDT
Recruiting No phase listed Observational

A Postmarketing Study of LEQEMBI in South Korean Participants With Alzheimer's Disease

NCT06810960
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
No Intervention
Other
Lead sponsor
Eisai Korea Inc.
Industry
Eligibility
19 Years and older
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Nutley, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Oct 14, 2026, 9:03 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic and Pharmacodynamic Study in Healthy Subjects Comparing the Interactions Between E5501 and Verapamil and Cyclosporine.

NCT01437384
View directory record Official record
Conditions
Idiopathic Thrombocytopenic Purpura (ITP)
Interventions
E5501
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2011
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated May 21, 2012 · Synced Oct 14, 2026, 9:03 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic Properties of Lorcaserin in Subjects With Hepatic Impairment

NCT00828932
View directory record Official record
Conditions
Hepatic Impairment
Interventions
Lorcaserin
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Sep 12, 2019 · Synced Oct 14, 2026, 9:03 AM EDT
Terminated Phase 2 Interventional Results available

A Study of MORAb-202 in Participants With Previously Treated Metastatic Non-Small Cell Lung Cancer (NSCLC) Adenocarcinoma (AC)

NCT05577715
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
MORAb-202
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
13
States / cities
Orange, California • Lone Tree, Colorado • Clermont, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2025 · Synced Oct 14, 2026, 9:03 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect on 24-hour, Intragastric pH of RAB ER 50-mg Capsules Compared With Esomeprazole (Nexium) 40 mg Capsules and Rabeprazole (Aciphex) 20-mg Tablets

NCT01153659
View directory record Official record
Conditions
Healthy
Interventions
E3810, Aciphex (rabeprazole), Nexium (esomeprazole)
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Nov 1, 2013 · Synced Oct 14, 2026, 9:03 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

An Study to Determine the Bioavailability of E2609 Tablets Compared to Capsules and the Effect of Food on Absorption

NCT01716897
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
E2609
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
30 Years to 55 Years · Male only
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated May 22, 2013 · Synced Oct 14, 2026, 9:03 AM EDT
Completed Phase 2 Interventional

A Safety and Efficacy Study of Intravenous E5564 in Patients With Severe Sepsis

NCT00046072
View directory record Official record
Conditions
Sepsis, Shock, Septic, Sepsis Syndrome, Septicemia, Infection
Interventions
E5564
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
17
States / cities
Mobile, Alabama • San Diego, California • Santa Barbara, California + 14 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2005 · Synced Oct 14, 2026, 9:03 AM EDT
Completed Phase 2 Interventional

Post-nasal Drainage as an Extraesophageal Manifestation of Reflux

NCT00199953
View directory record Official record
Conditions
Postnasal Drainage
Interventions
Rabeprazole 20 mg twice a day for 90-day period treatment
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years to 70 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 30, 2017 · Synced Oct 14, 2026, 9:03 AM EDT
Completed Phase 1 Interventional

A Study of ZYC300 Administered With Cyclophosphamide Pre-Dosing

NCT00381173
View directory record Official record
Conditions
Breast Cancer, Ovarian Cancer, Prostate Cancer, Colon Cancer, Renal Cancer
Interventions
Cyclophosphamide & ZYC300 (ZYC300 with cyclophosphamide pre-dosing)
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
2
States / cities
Boston, Massachusetts • Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 14, 2013 · Synced Oct 14, 2026, 9:03 AM EDT
Active, not recruiting Phase 2 Interventional Results available

A Phase 2 Study of Eribulin Followed by AC as Preoperative Therapy for HER2-negative Inflammatory Breast Cancer

NCT02623972
View directory record Official record
Conditions
Inflammatory Breast Cancer, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
Interventions
Eribulin, Adriamycin, Cyclophosphamide
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 14, 2026, 9:03 AM EDT
Recruiting Phase 2 Interventional

Phase II Study of Pembrolizumab in Combination With Lenvatinib in Patients With TNBC, NSCLC, and Other Tumor Types and Brain Metastases

NCT05064280
View directory record Official record
Conditions
Brain Metastases, Tumor
Interventions
Pembrolizumab, Lenvatinib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 14, 2026, 9:03 AM EDT
Completed Phase 3 Interventional Results available

Lenvatinib in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With Advanced Endometrial Cancer (MK-3475-775/E7080-G000-309 Per Merck Standard Convention [KEYNOTE-775])

NCT03517449
View directory record Official record
Conditions
Endometrial Neoplasms
Interventions
Pembrolizumab, Lenvatinib, Paclitaxel, Doxorubicin
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
827 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
25
States / cities
Phoenix, Arizona • San Francisco, California • Santa Monica, California + 22 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced Oct 14, 2026, 9:03 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

E7050 in Combination With Cisplatin and Capecitabine Versus Cisplatin and Capecitabine Alone in Patients With Advanced or Metastatic Solid Tumors and Previously Untreated Gastric Cancer

NCT01355302
View directory record Official record
Conditions
Advanced or Metastatic Solid Tumors, Previously Untreated Gastric Cancer
Interventions
E7050, cisplatin, capecitabine
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
9
States / cities
Tucson, Arizona • Plantation, Florida • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated May 15, 2017 · Synced Oct 14, 2026, 9:03 AM EDT
Completed Phase 2 Interventional Results available

Pembrolizumab Plus Lenvatinib for First-line Advanced/Metastatic Non-clear Cell Renal Cell Carcinoma (1L nccRCC) (MK-3475-B61)

NCT04704219
View directory record Official record
Conditions
Renal Cell Carcinoma
Interventions
Pembrolizumab, Lenvatinib
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 120 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
8
States / cities
Washington D.C., District of Columbia • Billings, Montana • Las Vegas, Nevada + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2025 · Synced Oct 14, 2026, 9:03 AM EDT